For example, CAR-NK cells targeting the B-cell maturation antigen (BCMA) have shown efficacy in preclinical models of multiple myeloma, and CAR-NK cells targeting HER2 have demonstrated antitumor activity in models of HER2-positive solid tumors. Here, TNFRSF17 is linked to plasma cell myeloma.